Prognostic Value of Early Fluorodeoxyglucose-Positron Emission Tomography Response Imaging and Peripheral Immunologic Biomarkers: Substudy of a Phase II Trial of Risk-Adaptive Chemoradiation for Unresectable Non-Small Cell Lung Cancer.

Adv Radiat Oncol · 2022 · PMC8977846 · PMID 35387421

Europe PMC DOI

hedged sentence

0.4500

closest p · 9.0× alpha

0.4500

boldest claim

The sentences

did not reach statistical significanceP = .45not close (p > 0.1)

Receipt of consolidation durvalumab according to the PACIFIC regimen resulted in numerically higher PFS but did not reach statistical significance in our trial cohort (median PFS 19.4 vs 10.9 months, log rank P = .45).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.